A
Aera Therapeutics
Biotech & Life Sciences · Boston, United States · Founded 2021
Aera is developing a new class of genetic medicines based on its proprietary crispr-based platform MoreLess
Aera Therapeutics is a pioneering genetic medicines company focused on developing transformative treatments for a wide range of human diseases. The company leverages its proprietary protein nanoparticle (PNP) delivery platform, which utilizes endogenous human proteins that self-assemble into capsid-like structures capable of packaging and transferring nucleic acid cargo. This innovative approach aims to harness the power of genetic medicines to address unmet medical needs across various therapeutic applications.
Aera serves a diverse clientele, including patients, healthcare providers, and pharmaceutical partners. Operating in the biotechnology and pharmaceutical markets, the company employs a business model centered around research and development (R&D), clinical trials, and strategic partnerships. Revenue is generated through the development and commercialization of genetic medicine therapies, as well as potential collaborations and licensing agreements with other biotech and pharmaceutical companies.
Under the leadership of CEO Akin Akinc, Ph.D., who brings extensive experience from his tenure at Alnylam Pharmaceuticals, Aera is well-positioned to advance its mission of delivering innovative genetic treatments. The company offers a competitive benefits package to attract top talent and foster a supportive work environment.
Keywords: genetic medicines, protein nanoparticle, nucleic acid delivery, therapeutic applications, biotechnology, pharmaceutical, R&D, clinical trials, strategic partnerships, innovative treatments.
Company overview
Aera Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2021
- Headquarters
- Boston, United States
- Employees
- 88
- Open positions
- 5
- Dealroom signal
- 45.4
Valuation & funding
Aera Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Feb 2023 | $58M | $232M | GV · Lux Capital · ARCH Venture Partners | ↗ |
| SERIES BOther financing | Jan 2023 | $135M | $540M | Lux Capital · GV · ARCH Venture Partners | ↗ |
| SPINOUTOther financing | Jan 2021 | $0 | — | Massachusetts Institute of Technology · Broad Institute | — |
Growth signals
Aera Therapeutics website traffic
Latest recorded traffic for Aera Therapeutics is 3.7K monthly website visits, up 15.6% over the last three months. Aera Therapeutics's team grew 7.3% over the past year.
Hiring
Open positions at Aera Therapeutics
Current openings linked to this company in Dealroom.
Comparisons
Aera Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Aera Therapeutics's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Aera Therapeutics has talent and traffic
team presence
In the news
Latest news about Aera Therapeutics
Recent press, funding announcements, and product moves mentioning Aera Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about Aera Therapeutics
An AI-synthesized read of the highest-engagement posts about Aera Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Aera Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.